Publication in refereed journal
香港中文大学研究人员 ( 现职)
| 陈力元教授 (内科及药物治疗学系) |
| 陈林教授 (肿瘤学系) |
全文
| 数位物件识别号 (DOI) http://dx.doi.org/10.1200/JCO.2015.61.5724 |
引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/18WOS source URL
其它资讯
摘要Infection is a well-described cause of cancer in humans. Being one of the most common infections worldwide, hepatitis B virus (HBV) is the leading cause of hepatocellular carcinoma (HCC), particularly in Asian countries. The etiological link between HBV and HCC provides an important opportunity for health care policy makers and clinicians to intervene with HBV infection to prevent cancer development and improve the outcomes of cancer. This review aims to use HBV as an example to illustrate the potential of tackling infection-related conditions to help improve cancer outcomes. This article is divided into four parts: In the first part, an overview is given on the epidemiologic data and risk factors of HCC development in patients with chronic hepatitis B. In the second part, recent progress on the anti-HBV strategies for preventing HCC is updated. In the third part, approaches to improve the outcomes of established HBV-related HCC are covered. These methods include surveillance strategies to identify asymptomatic HCC among patients with chronic HBV infection, and use of antiviral treatment to avoid HBV reactivation during treatment for HCC and reduce the recurrence of HCC after curative treatment. Finally, the status of the development of targeted drugs specifically for HBV-related HCC is discussed in the section on future development. (C) 2015 by American Society of Clinical Oncology. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/
着者Chan SL, Wong VWS, Qin SK, Chan HLY
期刊名称Journal of Clinical Oncology
出版年份2016
月份1
日期1
卷号34
期次1
出版社AMER SOC CLINICAL ONCOLOGY
页次83 - 90
国际标準期刊号0732-http://aims.cuhk.edu.hk/converis/portal/Publication/183X
电子国际标準期刊号1527-7755
语言英式英语
Web of Science 学科类别Oncology
